Urovant Sciences named one of the 2021 Best Places to Work in Orange County!
recognition

Mission and Values

Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for a range of urologic conditions.

Our goal is to be the leading specialty company, recognized and trusted by patients and providers for our commitment to urology.

At Urovant Sciences, we aim to advance urological patient care through execution of our core values:

Integrity and Compassion

Our commitment to improving patient lives begins with integrity, dignity and equity.

Bold Innovation Through Inclusion

We deliver bold innovation through openness to new ideas, listening to different voices, and adapting to change. 

Achievement Through Collaboration

We achieve excellence by uniquely optimizing our collective individual differences and expertise as strengths.

Urovant Sciences is driving scientific innovation to improve the quality of life for patients living with urological conditions.
Our current area of research focus is Overactive Bladder (OAB). We are currently investigating treatments for OAB in men with benign prostatic hyperplasia (BPH), as well as third line treatments for OAB symptoms in patients who have failed oral pharmacologic therapy.
Every team member has the ability to make an impact to our success.
At Urovant Sciences, we are Powered by People and Possibilities™. Every employee contributes to driving us forward. We each bring passion, purpose and care to our work and we are bold in our approach to improve outcomes for patients and healthcare providers. We succeed through grit, determination, flexibility and hard work and offer an encouraging and rewarding community where careers can flourish.
Working

Our History

Founded in 2017, Urovant Sciences is a biopharmaceutical company committed to advancing innovative therapies for urological care.

2017
Vibegron, a β3-adrenergic agonist in development to treat symptoms of overactive bladder (OAB), is acquired as the first compound in the portfolio.
Urovant Sciences establishes corporate offices in Irvine, California.
2018
Urovant Sciences raises $140M in its initial public offering on the NASDAQ Global Select Market under the symbol UROV.
Acquisition of URO-902, the second compound in the portfolio, kickstarts the development of a gene therapy for the treatment of symptoms of OAB.
Phase 3 study of vibegron for patients with OAB begins.
2019
Urovant Sciences launches the Phase 3 study of vibegron for men with benign prostatic hyperplasia (BPH) and OAB.
Phase 2 study of URO-902 for patients with OAB begins.
Primary shareholder, Roivant Sciences, sells its majority ownership of Urovant Sciences to Sumitovant Biopharma Ltd., which is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd.
Urovant Sciences files New Drug Application (NDA) with U.S. Food and Drug Administration for vibegron in OAB.
2020
Executed two collaboration agreements, including the primary care co-promotion agreement with Sunovion.
Reached agreement with Sumitomo Dainippon Pharma to invest in Urovant’s business and for the merger with Sumitovant.
Achieved on-time approval by the U.S. Food & Drug Administration of Urovant’s first commercial product, GEMTESA® (vibegron) 75 mg tablets for patients with OAB on December 23.
2021
Advanced development pipeline, including advancing URO-902, the novel gene therapy being investigated as a treatment for OAB.
Urovant Sciences team grows to 300 employees after onboarding 155 national field sales representatives.
Sumitovant and Urovant Sciences completed merger on March 29.
Urovant Sciences announces U.S. commercial launch of GEMTESA for adult patients with OAB.
Urovant Sciences and Sunovion Pharmaceuticals launch primary care co-promotion of GEMTESA for OAB patients.
Orange County Business Journal names Urovant Sciences one of the 2021 Best Places to Work in Orange County, California.
Urovant Sciences is committed to developing medicines for urological conditions that allow people to live healthier and happier lives.
Our approach is rooted in social responsibility. We are committed to the health and well-being of the patients and healthcare providers we serve, to our employees, and to the communities in which we operate. Urovant Sciences supports policies that improve public health and access to life-impacting therapies regardless of race, ethnicity or ability to pay.
Jim Robinson
Jim Robinson
President & Chief Executive Officer
Ryan Card
Ryan Card
EVP & General Counsel
Alana Darden Powell
Alana Darden Powell
Vice President of Corporate Communications
CHRO
Betzy Estrada
EVP & Chief Human Resources Officer
Laura Genatossio
Laura Genatossio
Senior Vice President and General Manager, Europe
Cornelia Haag-Molkenteller
Cornelia Haag-Molkenteller, MD, PhD
EVP & Chief Medical Officer
Walt Johnston Image
Walt Johnston
EVP, Commercial
Mark Niemaszek
Mark Niemaszek
Senior Vice President of Corporate Planning
Kenton Stewart Image
Kenton Stewart
EVP, Market Access and Business Development
Myrtle Potter Image
Myrtle Potter
Yuichiro Haruyama
Yuichiro Haruyama
Jim Hindman
Jim Hindman
Sef Kurstjens Image
Sef Kurstjens, MD, PhD
Pierre Legault
Pierre Legault
Shigeyuki Nishinaka Image
Shigeyuki Nishinaka, PhD
Jim Robinson
Jim Robinson
Patent Notice
Please see the following list for U.S. Patents covering Urovant Sciences' Products.